Last reviewed · How we verify
Doxazosin (drug)
Doxazosin (drug) is a Alpha-1 adrenergic receptor antagonist Small molecule drug developed by Japan Heart Foundation. It is currently FDA-approved for Hypertension, Benign prostatic hyperplasia with lower urinary tract symptoms.
Doxazosin is an alpha-1 adrenergic receptor antagonist that blocks norepinephrine signaling in blood vessels and the prostate, causing vasodilation and smooth muscle relaxation.
Doxazosin is an alpha-1 adrenergic receptor antagonist that blocks norepinephrine signaling in blood vessels and the prostate, causing vasodilation and smooth muscle relaxation. Used for Hypertension, Benign prostatic hyperplasia with lower urinary tract symptoms.
At a glance
| Generic name | Doxazosin (drug) |
|---|---|
| Sponsor | Japan Heart Foundation |
| Drug class | Alpha-1 adrenergic receptor antagonist |
| Target | Alpha-1 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular; Urology |
| Phase | FDA-approved |
Mechanism of action
Doxazosin selectively inhibits alpha-1 adrenergic receptors on vascular smooth muscle and in the prostate. This blockade reduces peripheral vascular resistance, lowering blood pressure, and also relaxes smooth muscle in the bladder neck and prostate, improving urinary flow. The drug is used for both hypertension and benign prostatic hyperplasia.
Approved indications
- Hypertension
- Benign prostatic hyperplasia with lower urinary tract symptoms
Common side effects
- Dizziness
- Fatigue
- Headache
- Syncope (first-dose effect)
- Palpitations
- Edema
Key clinical trials
- Alpha-1 Blockade for Alcohol Use Disorder (AUD) (PHASE2)
- Doxazosin an a1 Antagonist for Alcohol Dependence (EARLY_PHASE1)
- Effect of Anti-hypertensive Medications on the Diagnostic Accuracy in Primary Aldosteronism
- Treating Nightmares in Posttraumatic Stress Disorder With Clonidine and Doxazosin (PHASE2)
- Doxazosin and Ramipril in Hypertension (PHASE4)
- Phenoxybenzamine Versus Doxazosin in PCC Patients (PHASE4)
- A Randomized Controlled Trial of Doxazosin for Nightmares, Sleep Disturbance, and Non-Nightmare Clinical Symptoms in PTSD (PHASE2)
- Genetics of Hypertension Associated Treatments (GenHAT)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Doxazosin (drug) CI brief — competitive landscape report
- Doxazosin (drug) updates RSS · CI watch RSS
- Japan Heart Foundation portfolio CI
Frequently asked questions about Doxazosin (drug)
What is Doxazosin (drug)?
How does Doxazosin (drug) work?
What is Doxazosin (drug) used for?
Who makes Doxazosin (drug)?
What drug class is Doxazosin (drug) in?
What development phase is Doxazosin (drug) in?
What are the side effects of Doxazosin (drug)?
What does Doxazosin (drug) target?
Related
- Drug class: All Alpha-1 adrenergic receptor antagonist drugs
- Target: All drugs targeting Alpha-1 adrenergic receptor
- Manufacturer: Japan Heart Foundation — full pipeline
- Therapeutic area: All drugs in Cardiovascular; Urology
- Indication: Drugs for Hypertension
- Indication: Drugs for Benign prostatic hyperplasia with lower urinary tract symptoms
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing